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Whether insomnia, a known correlate of depression, predicts depression longitudinally warrants elucidation. The
authors examined 555 Wisconsin Sleep Cohort Study participants aged 33–71 years without baseline depression
or antidepressant use who completed baseline and follow-up overnight polysomnography and had complete
questionnaire-based data on insomnia and depression for 1998–2006. Using Poisson regression, they estimated
relative risks for depression (Zung scale score 50) at 4-year (average) follow-up according to baseline insomnia
symptoms and polysomnographic markers. Twenty-six participants (4.7%) developed depression by follow-up.
Having 3–4 insomnia symptoms versus none predicted depression risk (age-, sex-, and comorbidity-adjusted
relative risk (RR) ¼ 3.2, 95% conﬁdence interval: 1.1, 9.6). After multiple adjustments, frequent difﬁculty falling
asleep (RR ¼ 5.3, 95% conﬁdence interval: 1.1, 27.9) and polysomnographically assessed (upper or lower
quartiles) sleep latency, continuity, and duration (RRs ¼ 2.2–4.7; P ’s  0.05) predicted depression. Graded
trends (P-trend  0.05) were observed with increasing number of symptoms, difﬁculty falling asleep, and difﬁculty
returning to sleep. Given the small number of events using Zung 50 (depression cutpoint), a limitation that may
bias multivariable estimates, continuous depression scores were analyzed; mean values were largely consistent
with dichotomous ﬁndings. Insomnia symptoms or markers increased depression risk 2.2- to 5.3-fold. These results
support prior ﬁndings based on self-reported insomnia and may extend similar conclusions to objective markers.
Heightened recognition and treatment of insomnia may prevent subsequent depression.
depression; polysomnography; prospective studies; sleep; sleep initiation and maintenance disorders

Abbreviations: RR, relative risk; SD, standard deviation.

To date, studies of insomnia and depression have largely
conceptualized insomnia as a clinical correlate or component
of depression—that is, as a prodromic sign or symptom (1, 2),
a precursor (3, 4), or its most persistent residual symptom
after treatment (5). Insomnia’s strong cross-sectional association and high comorbidity with depression and other mood
disturbances have been well-established in epidemiologic
studies (6–12). However, insomnia is increasingly being recognized as a possible contributor to the development of
depression (13).
Elucidating insomnia’s prospective relation to subsequent
depression could lead to improved recognition, treatment,
and prevention of depression, which is projected to rank as
the second-leading cause of lost disability-adjusted life
years after ischemic heart disease by 2020 (14). Both in-

somnia (15) and depression (16, 17) are highly prevalent,
persistent, undertreated, and costly (18) disorders related to
significant functional impairment and disability (17–19), including increased absenteeism (15, 20) and health-care utilization (9, 17, 19).
Prior prospective studies have found that self-reported insomnia predicts depression in varied populations (3, 12, 13,
21–29), including younger (12, 26, 27) and older (13, 28, 29)
adults. However, with scant exceptions (12, 22, 25–28), most
studies of insomnia and depression have been limited to
shorter follow-up periods—1 year (3, 9, 10, 21, 23, 24) or 2
years (29, 30)—and all have been limited to self-reported
assessment of insomnia. Furthermore, while electroencephalographic sleep abnormalities reflecting insomnia (31–34)
have been cross-sectionally correlated with depression in
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psychiatric populations, prospective relations of polysomnographic insomnia markers to depression have not been studied in clinical or population-based samples. Thus, insomnia’s
longitudinal consequences are still poorly understood (35).
We investigated whether objective markers and selfreported symptoms of insomnia would predict depression
symptoms at 4-year follow-up in a large population-based
sample that was free of depression at baseline. We hypothesized that polysomnographic markers of insomnia—namely,
decreased sleep duration, poorer sleep continuity, longer
sleep latency, and increased insomnia symptom frequency—
would predict the incidence of depression in a graded (‘‘doseresponse’’) fashion.
MATERIALS AND METHODS
Participants and data collection

The study procedures were approved by the University of
Wisconsin-Madison Health Sciences Institutional Review
Board. The sample comprised participants enrolled in the
ongoing Wisconsin Sleep Cohort Study, previously described (36). Participants provided signed informed consent.
A stratified random sample of previously surveyed
Wisconsin state employees (n ¼ 2,884) was invited to participate in a baseline overnight sleep study, and 53% (n ¼
1,533) agreed; the primary reported reason for nonparticipation was the burden of sleeping overnight in a sleep
laboratory. Overnight protocols included nocturnal polysomnography at participants’ usual sleep times; clinical assessments, including calculation of body mass index (weight
(kg)/height (m)2); administration of a depression scale; and
completion of a questionnaire regarding health history, sleep
habits, and insomnia symptoms. Approximately every 4
years after baseline studies, participants are invited to undergo follow-up examinations; by June 2008, there was an
average follow-up participation rate of 80%.
Of 1,533 cohort participants, 787 were initially eligible
for the present analyses, since they had completed overnight
polysomnography between 1998 and 2002 and had undergone follow-up polysomnography 3–5 years later (average,
4 years) and had complete baseline and follow-up data on
depression and self-reported insomnia for the period 1998–
2006. Insomnia symptoms were first assessed during overnight protocols in 1998. For examination of incident
depression, participants who had symptoms of depression
(Zung score 50) or were taking antidepressant medication
at baseline (n ¼ 192) were excluded from the current analyses, which left 595 participants at risk for subsequent depression. Additionally, 40 participants who, at follow-up,
were on antidepressant medication yet reported no depression symptoms (Zung score <50) were excluded from analyses, to limit potential bias related to overestimation of
insomnia’s association with depression. Thus, the final inception cohort for this analysis constituted 555 participants.
Insomnia
Self-reported symptoms. The health questionnaire included 4 items on insomnia: difficulty in getting to sleep

(referred to as difficulty in falling asleep or initiating sleep),
waking up repeatedly during the night (repeated nocturnal
awakenings), waking up too early in the morning and being
unable to get back to sleep (awakening too early), and waking up during the night and having a hard time getting back
to sleep (difficulty getting back asleep). Response categories
were never or rarely (once/month), sometimes (2–4 times/
month), often (5–15 times/month), and almost always (16–
30 times/month). Each item was dichotomized into often/
almost always (5 times/month) versus sometimes/less (<5
times/month), and then a number-of-symptoms (0, 1, 2, 3, or
4) variable was created at the frequency of often/almost
always. Another 4-level variable was created for individual
symptom frequency: 0 represented having all symptoms
never/rarely; 1, having the symptom of interest sometimes;
and 2, having the symptom of interest often/almost always.
The category ‘‘any other symptom sometimes or more often’’ differentiated the symptom of interest from other
symptoms.
Polysomnographically assessed markers. Data on sleep
latency, waking after sleep onset, sleep efficiency, and total
sleep time were obtained during the overnight protocol by
means of full 18-channel polysomnography (Grass Heritage
PSG Digital Sleep System with model 15A54 amplifiers;
Grass Technologies, West Warwick, Rhode Island) including electrooculography, electroencephalography, and electromyography. Sleep stage for each 30-second epoch was
scored by technicians, according to conventional criteria
(37). ‘‘Sleep latency’’ was defined as amount of time (minutes) from ‘‘lights off’’ to the first of 3 consecutive epochs of
stage 1 sleep or the first epoch of any other stage of sleep;
‘‘waking after sleep onset’’ as the amount of time (minutes)
spent awake after first sleep onset; ‘‘total sleep time’’ as the
total amount of time spent sleeping (minutes); and ‘‘sleep
efficiency’’ (%) as the proportion of total sleep time out of
total duration of time in bed from ‘‘lights out.’’
Outcome: depression

On the same evening as the overnight studies, participants
completed the Zung Self-Rating Depression Scale (38) and
provided information on regularly taken medications, including antidepressants (selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase
inhibitors, or other). Scores on the 20-item Zung scale range
from 25 to 100. Scores less than 50 indicate ‘‘normal’’ (not
depressed), and scores greater than or equal to 50 are considered indicative of depression (37). We used this standard
cutpoint for our population-based sample rather than
a higher threshold (perhaps better-suited for a clinical
sample). The original instructions, ‘‘how you have been
feeling in the past few days,’’ were modified, and participants were instructed, ‘‘Please read each of the following
statements and place an X in the box which best describes
how you feel in general from day to day.’’ For these analyses, we used a ‘‘modified’’ Zung scale that excluded 2 items
(‘‘I have trouble sleeping through the night’’ and ‘‘I get
tired for no reason’’) which may indicate insomnia and
result in a built-in association between insomnia and
depression. After exclusion of these items, the score was
Am J Epidemiol 2010;171:709–720
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rescaled for comparability to the original 20-item Zung
scale, as previously reported (39).
Covariates included age, sex, clinically assessed body
mass index, and variables from a self-administered health
questionnaire: moderate/greater alcohol consumption (2
daily drinks of beer, wine, or hard liquor vs. less); cigarette
smoking (current, past, or never); caffeine consumption (0,
1–2, 3–4, or 5 caffeinated beverages daily); use of hypnotic agents; and self-report of any physician-diagnosed
chronic illness (coronary artery disease, congestive heart
failure, angina, hypertension, stroke, diabetes, asthma, emphysema, thyroid condition, epilepsy, arthritis, or back
pain). Sleep-disordered breathing status was assessed by
polysomnography and summarized as numbers of apnea
events (complete cessation of nasal and oral airflow for >10
seconds) and hypopnea events (decrease in respiratory effort
associated with a >4% drop in arterial oxygen saturation)
per hour of sleep (apnea-hypopnea index). Using conventional
cutpoints (37), apnea-hypopnea index was categorized as <5
(little or no sleep-disordered breathing), 5–<15 (mild),
or 15 (moderate or worse).
Statistical analysis

In descriptive analyses, we examined average continuous
baseline Zung scores in participants with Zung scores less
than 50 to ensure that associations between insomnia and
depression were not attributable to participants with insomnia symptoms or markers having subthreshold depression
(higher scores near 50). Using analysis of variance, we
tested for any (F test) or pairwise (t tests) significant differences between mean continuous Zung scores less than 50 (at
baseline) and objectively measured (sleep latency and
quartiles of total sleep time) and self-reported (number of
symptoms) insomnia.
In unadjusted analyses, categorical differences were
tested using the Pearson v2 test and the Mantel-Haenszel
v2 trend test. Regression models were used to estimate adjusted relative risks and 95% confidence intervals for depression with respect to insomnia at baseline (1998–2002).
Persons with incident depression symptoms were included
in all analyses, irrespective of antidepressant use at followup. Depression at follow-up was only assessed at 4 years, on
average. Analyses, carried out with Proc Genmod in SAS
(SAS Institute Inc., Cary, North Carolina), assumed a
Poisson distribution with robust error variances (40),
a log-link function, and an unstructured variance-covariance
structure. A P value less than or equal to 0.05 (2-sided) was
considered significant.
Relations of polysomnographic markers to subsequent
depression were initially assessed using quartile groupings
obtained from the overall cohort (quartile cutpoints (25th percentile, median, 75th percentile): sleep latency (minutes)—
4, 8, and 14; waking after sleep onset (minutes)—31, 48.5,
and 78.5; sleep efficiency—78%, 85%, and 91%; total sleep
time (minutes)—334, 374.5, and 409). Because linear relations were present only for total sleep time, we constructed
binary variables for the remaining markers. For sleep latency
and waking after sleep onset, the uppermost quartiles (14
minutes and 79 minutes, respectively) represented marker
Am J Epidemiol 2010;171:709–720
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presence; the other quartiles combined constituted the reference categories. Sleep efficiency was represented by the lowest quartile (<78%) and its referent by the upper quartiles
combined. Given total sleep time quartiles’ graded relation to
depression and the significant (P  0.02) linear relation observed when total sleep time was examined continuously, its
quartiles were not combined.
Adjusted models included potentially confounding variables in 2 stages: 1) age, sex, and chronic health conditions;
and 2) alcohol, smoking, caffeine, hypnotics, and body mass
index. Two-way interactions of insomnia with age and sex
were assessed.
Linear trends (with insomnia examined as a continuous
variable) in the logarithms of relative risks were tested for
significance in Poisson regression models. In individual insomnia symptom models, linear trends were tested for the
reference, symptom-of-interest ‘‘sometimes,’’ and symptomof-interest ‘‘often/always’’ categories (the ‘‘other symptom’’ category was excluded from trend tests) with adjustment for age, sex, and comorbidity but not full adjustment,
because of nonconvergence of insomnia categories in these
models.
In secondary analyses, after confirming the normality of
continuous depression scores at follow-up and of depression’s residuals, we conducted linear regression analysis to
examine continuous depression scores (modified Zung
scale) at follow-up for every insomnia variable modeled
separately, with age, sex, and comorbidity adjustments as
in the discrete-outcome (Zung score 50) models. Persons
with depression (according to the modified Zung scale or
antidepressant use) at baseline were excluded from these
analyses; thus, all analyses were conducted in the same inception sample (n ¼ 555). Overall F tests for insomnia variables were conducted first; if results were significant,
individual t tests were conducted.
We examined sleep-disordered breathing as a potential
confounder by adjusting for apnea-hypopnea index in regression models. Furthermore, we examined insomnia’s association with depression symptoms after removing from
the analyses participants with anxiety at baseline, defined
by use of anxiolytic agents and/or a trait-anxiety score at or
above the 75th percentile using the State-Trait Anxiety Inventory (41), which was self-administered during overnight
studies. The cutpoint for anxiety (Trait Anxiety score 39)
was defined by the overall cohort’s 75th percentile. The
correspondence of insomnia symptoms to polysomnographic measures was assessed for the same overnight study
among 337 participants who reported that sleep obtained
during their polysomnography study was typical of, or not
much different from, their usual sleep.

RESULTS

The average follow-up period was 3.8 years (standard deviation (SD), 0.4). Of the initial subset (n ¼ 787), 54% of
participants were male; the mean age was 53.6 years (SD,
7.7; range, 33–71). Baseline characteristics are shown in
Table 1. Relatively high proportions of self-reported insomnia symptoms (e.g., 34% for repeated nocturnal awakenings)
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Table 1. Baseline Characteristics of Participantsa (n ¼ 555),
Wisconsin Sleep Cohort Study, 1998–2002
Characteristic

No.

%

333

60.0

47

8.5

101

18.2

Consumption of >1 alcoholic
drink/day

29

5.2

Use of hypnotic medication

11

2.0

Age, years
Male sex

54.0 (7.7)

Body mass indexb
Current smoking
Consumption of >4 caffeinated
drinks/day

Mean (SD)

31.1 (6.7)

Zung depression score

36.7 (5.6)

Self-reported insomnia symptoms
No. of insomnia symptoms
experienced often or
almost always
0

307

55.3

1

154

27.8

2

59

10.6

3 or 4

35

6.3

54

9.7

188

33.9

93

16.8

101

18.2

Difﬁculty falling asleep
(often/almost always)
Repeated nocturnal awakenings
(often/almost always)
Difﬁculty getting back to sleep
during the night
(often/almost always)
Early morning awakening
(often/almost always)
Polysomnographically assessed
markers of insomnia

Insomnia symptoms

Waking after sleep onset,
minutes

68.4 (44.1)

Total sleep time, minutes

375.5 (62.8)

Sleep latency, minutes

11.6 (13.0)

Sleep efﬁciency, %

81.9 (10.8)

Chronic health conditions
Asthmac

64

Diabetesc

62

11.2

187

33.7

49

8.8

230

41.4

Hypertensionc
Cerebrocardiovascular
diseasec
Other conditionsd

Baseline mean depression scores (Zung score <50) in participants who developed (Zung score 50) or did not develop
(Zung score <50) depression were similar: 40.0 (SD, 6.07)
and 36.6 (SD, 5.5), respectively. Average scores changed
(follow-up minus baseline) by þ13.4 points versus only
0.01 points for participants developing, versus not developing, depression. Baseline average depression scores in participants without depression (Zung score <50) were not
significantly different (P ¼ 0.74) for decreasing total sleep
time quartiles (Zung scores were 36 (quartile 4—longest,
‘‘best’’ total sleep time), 37 (quartile 3), 37 (quartile 2), and
34 (quartile 1—shortest, ‘‘worst’’ sleep time)) or increasing
sleep latency (Zung scores were 37 (quartile 1—shortest,
‘‘best’’), 36 (quartile 2), 36 (quartile 3), and 37 (quartile
4—longest, ‘‘worst’’)). Despite statistical significance (P <
0.0001), average baseline Zung scores did not approach the
50 cutpoint for number of insomnia symptoms (36 for no
symptoms, 37 for 1 symptom, 38 for 2 symptoms, and 38
for 3 or 4 symptoms).
Figure 1 shows the unadjusted incidence of depression by
number of insomnia symptoms among participants who
were free of depression symptoms and antidepressant use
at baseline. Regardless of Zung depression scale (original or
modified with 2 sleep-related items removed) and antidepressant use at follow-up, an increasing incidence of depression was observed across insomnia symptoms. This trend
was significant for all categories (P-trend  0.02) except
‘‘modified Zung score excluding antidepressant users at
follow-up’’ (P-trend ¼ 0.06). Depression incidence for 3
or 4 symptoms was 3.2–3.6 times that for no symptoms
(irrespective of exclusion of antidepressant users).

11.5

Abbreviation: SD, standard deviation.
The baseline sample excluded participants who reported depressive symptoms (deﬁned as modiﬁed Zung depression scale
score 50) or use of antidepressant medication.
b
Weight (kg)/height (m)2.
c
Self-report of a physician’s diagnosis.
d
Self-report of a physician’s diagnosis of epilepsy, emphysema,
thyroid disease, arthritis, or back pain.
a

and polysomnographically defined markers were observed.
Twenty-six participants (4.7%) in the final inception cohort
had developed depression symptoms (Zung score 50) by
follow-up.

The number of symptoms occurring often/almost always
(Table 2) was found to be associated with subsequent depression in a graded (‘‘dose-response’’) fashion (P-trend ¼
0.02) after adjustment for age, sex, and comorbidity; the
relative risk for 3 or 4 symptoms was 3.23 (P ¼ 0.03).
Further adjustments attenuated this relation, though risk
was still increased, and the overall trend remained significant (P-trend ¼ 0.04).
Linear trends were observed for the relation of individual symptom frequency to incident depression symptoms
(Figure 2) and were significant for increasing difficulty
falling asleep (P-trend < 0.001) and increasing difficulty
getting back asleep (P-trend ¼ 0.02). After adjustment for
age, sex, and comorbid conditions, increasing difficulty
falling asleep and getting back asleep demonstrated significant graded trends for depression (P-trend ¼ 0.01 and
P-trend ¼ 0.03, respectively) (Table 3). Repeated nocturnal and early morning awakenings demonstrated nearsignificant trends (P-trend ¼ 0.07). Each symptom
experienced ‘‘often or always’’ (versus all symptoms experienced ‘‘never or rarely’’) was related to a 3-fold or
higher risk, though after full adjustment, risk was significant only for difficulty falling asleep (relative risk (RR) ¼
5.31; P ¼ 0.05).
No significant at (P  0.05) age or sex interactions were
observed for individual symptoms or number of symptoms.
Am J Epidemiol 2010;171:709–720
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Figure 1. Incidence of depression symptoms (%) at 4-year follow-up (2002–2006), obtained using different classiﬁcations of depression, by
number of insomnia symptoms at baseline (1998–2002) in Wisconsin Sleep Cohort Study participants (n ¼ 542–685). White columns, no
symptoms; columns, with squares, 1 symptom; striped columns, 2 symptoms; black columns, 3 or 4 symptoms. ‘‘Modiﬁed Zung score’’ refers
to the Zung depression scale (38) rescored after exclusion of 2 items on insomnia and tiredness. P-trend values for the relation of number of
insomnia symptoms to subsequent depression: for Zung score 50, P-trend ¼ 0.006; for Zung score 50 excluding antidepressant users at followup, P-trend ¼ 0.02; for modiﬁed Zung score 50, P-trend ¼ 0.02; and for modiﬁed Zung score 50 excluding antidepressant users at follow-up,
P-trend ¼ 0.06. Bars, standard error.

Polysomnographic markers

Unadjusted depression risk was 2- to 3-fold higher
for increased (uppermost quartile) sleep latency and waking after sleep onset and decreased (lowest quartile) sleep
efficiency and total sleep time, versus the respective
reference categories (Table 4). Significant associations
persisted after additional adjustments, with the full adjustment expressed by significant relative risks between
2.2 and 4.7, and a graded pattern for total sleep time
(P-trend ¼ 0.03).
Secondary analyses

The significant relation of number of symptoms to incident depression, including its graded pattern (P-trend 
0.05), was not altered by adding apnea-hypopnea index to
the age-, sex-, and comorbidity-adjusted model (RR ¼ 3.17,
95% confidence interval: 1.05, 9.61) or by excluding from
the analyses participants with anxiety at baseline (RR ¼
3.70, 95% confidence interval: 1.22, 11.18).
Clinical polysomnographic cutpoints were examined in
fully adjusted models. Sleep latency >30 minutes (vs. 30
minutes) (RR ¼ 3.98) and sleep efficiency <80%
(vs. 80%) (RR ¼ 4.39) significantly (P  0.01) predicted
depression; total sleep time <360 minutes (vs. 360 minAm J Epidemiol 2010;171:709–720

utes) (RR ¼ 1.53) and waking after sleep onset >30 minutes
(vs. 30 minutes) (RR ¼ 1.10) did not.
Increasing mean sleep latency (polysomnographically assessed) was related to increasing frequency of self-reported
difficulty falling asleep: 7.9 minutes—never (0 times/month),
9.3 minutes—rarely (once/month), 11.9 minutes—sometimes
(2–4 times/month), 14.9 minutes—often (5–15 times/month),
and 19.2 minutes—almost always (16–30 times/month). Increased mean waking after sleep onset (polysomnographically assessed) corresponded to increased self-reported
frequency of nocturnal awakening: 7.9 minutes—never, 9.3
minutes—rarely, 11.9 minutes—sometimes, 14.9 minutes—
often, and 19.2 minutes—almost always.
In our sample (n ¼ 555), results based on mean continuous scores for depression at follow-up (Table 5) largely
showed patterns similar to those based on a discrete outcome (Zung score 50), considered the clinical cutpoint
(38). Mean depression values for 7 of 9 insomnia variables—
number of symptoms, 4 individual symptoms, decreased
sleep efficiency, and increased waking after sleep onset—
were significantly increased upon follow-up and showed
graded trends for all insomnia symptoms (P-trend 
0.01). No associations were found for increased sleep
latency and decreased total sleep time. Results remained
unchanged after exclusion of antidepressant users from
follow-up (n ¼ 548).
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Table 2. Relative Risk of Incident Depressiona Symptoms at 4-Year Follow-up According to
Number of Insomnia Symptomsb Reported at Baseline (n ¼ 555), Wisconsin Sleep Cohort Study,
1998–2006
No. of
Insomnia
Symptomsc

Incidence of
Depression

Total
No. of
Participants

No.

0

307

11

3.58

1

154

6

3.90

2

59

5

8.47

3 or 4

35

4

11.43

95% CI

Fully
Adjustedf
RRg

1.00

Referent

1.00

Referent

1.12

0.43, 2.93

1.07

0.40, 2.90

2.62

0.92, 7.49

2.82

0.96, 8.21

3.23*

1.09, 9.57

2.49

0.83, 7.50

Adjustedd
RRe

%

95% CI

Abbreviations: CI, conﬁdence interval; RR, relative risk.
* P ¼ 0.03.
a
Depression was deﬁned as modiﬁed (without 2 sleep-related items) Zung depression scale
score 50.
b
Insomnia was deﬁned as having any insomnia symptom (difﬁculty falling asleep, difﬁculty
getting back to sleep after awakening during the night, waking up repeatedly during the night, or
early morning awakening) at a frequency of ‘‘often or almost always’’ (5 times/month).
c
Participants who reported depressive symptoms (deﬁned as modiﬁed Zung depression
score 50) or use of antidepressant medication at baseline were excluded.
d
Adjusted for age, sex, and chronic health conditions.
e
P ¼ 0.02 for linear trend in the logarithm of the relative risk.
f
Adjusted for age, sex, chronic health conditions, alcohol consumption, cigarette smoking,
caffeine consumption, use of hypnotic agents, and body mass index.
g
P ¼ 0.04 for linear trend in the logarithm of the relative risk.

DISCUSSION

Insomnia, whether assessed via polysomnographic
markers or via self-report, was found to be a risk factor
for depression symptoms at follow-up among participants
who had been free of depression 4 years earlier in our
population-based, observational study. Our study was
unique in that we assessed both polysomnographic markers
and self-reported symptoms of insomnia. Insomnia markers
reflecting decreased sleep continuity and its symptoms, in-

cluding number of symptoms and difficulty initiating sleep,
predicted the occurrence of depression after adjustment for
possible confounders. To our knowledge, significant graded
associations between insomnia (increasing number of symptoms, difficulty initiating and maintaining sleep) and depression have not been previously reported. Our findings
regarding self-reported insomnia’s positive relation to depression are broadly consistent with results from most prospective epidemiologic studies conducted in various US and

Figure 2. Incidence of depression symptoms (%) at 4-year follow-up (2002–2006) by frequency of insomnia symptoms at baseline (1998–2002)
in Wisconsin Sleep Cohort Study participants (n ¼ 555). White columns, never or rarely experienced symptom; striped columns, sometimes
experienced symptom; black columns, often or almost always experienced symptom. ‘‘am,’’ morning; ‘‘pm,’’ night. Bars, standard error.
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Table 3. Relative Risk of Incident Depressiona Symptoms at 4-Year Follow-up According to Baseline Frequency of 4 Individual Insomnia
Symptomsb (n ¼ 555), Wisconsin Sleep Cohort Study, 1998–2006
Model, Insomnia Symptom,
and Frequencyc

Total
No. of
Participants

Incidence of
Depression
No.

Adjustedd
RR

95% CI

%

Fully
Adjustede
RR

95% CI

Model 1: Difﬁculty falling asleep
All symptoms ‘‘never/rarely’’

100

2

2.00

1.00

Referent

1.00

Referent

Difﬁculty falling asleep ‘‘sometimes’’

185

13

7.03

3.41

0.78, 15.00

3.08

0.74, 12.77

54

6

11.11

216

5

2.32

Difﬁculty falling asleep ‘‘often/always’’
Any other symptom ‘‘sometimes/more often’’

6.05**

1.18, 31.08

5.31*

1.05, 27.87

1.25

0.24, 6.62

1.22

0.24, 6.37

Model 2: Difﬁculty getting back/returning to sleep
All symptoms ‘‘never/rarely’’

100

2

2.00

1.00

Referent

1.00

Referent

Difﬁculty returning to sleep ‘‘sometimes’’

202

11

5.45

2.95

0.63, 13.89

2.70

0.61, 11.94

93

8

8.60

4.42

0.93, 20.90

4.06

0.87, 18.97

160

5

3.13

1.57

0.31, 8.00

1.45

0.28, 7.61

Difﬁculty returning to sleep ‘‘often/always’’
Any other symptom ‘‘sometimes/more often’’
Model 3: Repeated nocturnal awakenings
All symptoms ‘‘never/rarely’’

100

2

2.00

1.00

Referent

1.00

Referent

Nocturnal awakenings ‘‘sometimes’’

138

7

5.07

2.46

0.52, 11.68

2.21

0.46, 10.57

Nocturnal awakening ‘‘often/always’’

188

12

6.38

3.40

0.74, 15.58

3.09

0.70, 13.58

Any other symptom ‘‘sometimes/more often’’

129

5

3.88

2.10

0.40, 10.91

2.06

0.41, 10.28

All symptoms ‘‘never/rarely’’

100

2

2.00

1.00

Referent

1.00

Referent

Early morning awakening ‘‘sometimes’’

157

8

5.10

2.75

0.56, 13.48

2.42

0.52, 11.36

Early morning awakening ‘‘often/always’’

101

7

6.93

3.79

0.78, 18.50

3.59

0.76, 16.84

Any other symptom ‘‘sometimes/more often’’

197

9

4.57

2.26

0.49, 10.35

2.16

0.49, 9.66

Model 4: Early morning awakening

Abbreviations: CI, conﬁdence interval; RR, relative risk.
* P ¼ 0.05; **P ¼ 0.03.
a
Depression was deﬁned as modiﬁed (excluding 2 sleep-related items) Zung depression scale score 50.
b
Insomnia symptoms deﬁned at a frequency of ‘‘never/rarely’’ refers to 1 occasion/month; ‘‘sometimes’’ refers to 2–4 times/month; ‘‘often/
always’’ refers to 5 times/month; and ‘‘sometimes/more often’’ refers to 2 times/month. ‘‘Difﬁculty falling asleep’’ is also referred to as ‘‘difﬁculty
initiating sleep.’’ ‘‘Difﬁculty getting back to sleep’’ and ‘‘repeated nocturnal awakenings’’ are considered variables related to difﬁculty in maintaining
sleep.
c
Participants who reported depressive symptoms (deﬁned as modiﬁed Zung depression score 50) or use of antidepressant medication at
baseline were excluded.
d
Adjusted for age, sex, and chronic health conditions.
e
Adjusted for age, sex, chronic health conditions, alcohol consumption, smoking cigarettes, hypnotic use, caffeine consumption, and body mass
index.

European populations (3, 12, 13, 21–24, 26–29), with a few
exceptions (10, 25, 30) possibly due to the use of differing
methods (e.g., insomnia definition or duration (12), sample
characteristics, follow-up periods).
An important limitation of our study is that only 26
(4.7%) participants developed depression (defined as Zung
score 50), since we emphasized specificity in our incident
depression classification. Because the small number of outcome events (defined dichotomously) may have led to biased multivariable regression estimates and confidence
intervals, we examined mean (continuous) depression
values at follow-up to help address this limitation. Analyses
based on mean scores were largely consistent with significant dichotomous results (based on the clinical cutpoint) and
showed similar patterns. Fully adjusted multivariable regression results also resembled minimally adjusted or nonadjusted results. Nevertheless, larger study samples yielding
Am J Epidemiol 2010;171:709–720

a greater number of incident depression events may be warranted for confirmation of our findings.
The associations we found were not likely to have been
due to subsyndromal depression in insomnia (scores near
Zung’s depression cutpoint). Average depression scores
did not differ at baseline according to higher levels of, versus lower or absent, polysomnographic markers and were
far from the depression cutpoint. For number of symptoms,
depression scores were merely 2 points higher for 3 or 4
symptoms versus no symptoms, and far (12 points) from the
50 threshold. Moreover, average Zung scores less than 50 at
baseline were similar for participants developing and not
developing depression.
Although the definition of insomnia sometimes includes
daytime consequences or impairment/interference (21, 42),
our definition did not, which limited the potential for built-in
associations. To avoid overestimating insomnia’s association
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Table 4. Relative Risk of Incident Depression Symptomsa at 4-Year Follow-up According to Insomnia Markersb
Measured Polysomnographically at Baseline (n ¼ 555), Wisconsin Sleep Cohort Study, 1998–2006
Insomnia Markerc

Total
No. of
Participants

Incidence of
Depression
No.

%

Fully
Adjustede
RR

Adjustedd
RR

95% CIc

1.10, 5.11

2.19*

1.02, 4.70

Referent

1.00

Referent

95% CIa

Sleep latency, minutes
14 (75th percentile)

132

11

8.33

2.37**

<14

422

15

3.55

1.00

79 (75th percentile)

185

15

8.11

3.84***

<79

370

11

2.97

1.00

<78 (<25th percentile)

169

15

8.88

4.40***

78

386

11

2.85

1.00

Referent

<334 (<25th percentile)

121

7

5.79

2.69

0.98, 7.47

3.18***

1.04, 9.74

334–<374.5

139

7

5.04

1.90

0.66, 5.49

2.10

0.67, 6.56

374.5–<409

135

7

5.19

1.64

0.55, 4.93

1.82

0.56, 5.92

409

160

5

3.13

1.00

Referent

1.00

Referent

Waking after sleep onset, minutes
1.84, 8.02
Referent

3.85***
1.00

1.81, 8.19
Referent

Sleep efﬁciency, %
2.22, 8.77

4.65***
1.00

2.30, 9.43
Referent

Total sleep time, minutes

P for trendf

0.05

0.03

Abbreviations: CI, conﬁdence interval; RR, relative risk.
* P ¼ 0.05; **P ¼ 0.03; ***P  0.001.
a
Depression was deﬁned as modiﬁed (excluding 2 sleep-related items) Zung depression scale score 50.
b
‘‘Sleep latency’’ was deﬁned as time (minutes) from ‘‘lights off’’ to the ﬁrst of 3 consecutive epochs of stage 1
sleep or the ﬁrst epoch of any other stage of sleep; ‘‘waking after sleep onset’’ was deﬁned as amount of time
(minutes) spent awake after ﬁrst sleep onset; ‘‘sleep efﬁciency’’ was deﬁned as proportion of total sleep time out
of time spent in bed from ‘‘lights out’’; and ‘‘total sleep time’’ was deﬁned as total time spent sleeping, in minutes.
c
Participants who reported depressive symptoms (deﬁned as modiﬁed Zung depression score 50) or use of
antidepressant medication at baseline were excluded.
d
Adjusted for age, sex, and chronic health conditions.
e
Adjusted for age, sex, chronic health conditions, alcohol consumption, cigarette smoking, use of hypnotic agents,
caffeine consumption, and body mass index.
f
P value for linear trend in the logarithm of the relative risk for total sleep time. Unlike the other polysomnographic
measures, total sleep time had a linear relation to depression; thus, quartiles are shown and the variable was not
dichotomized.

with depression, we used a modified depression scale
excluding 2 sleep-related items, a method rarely used (10,
26). Estimates, though slightly attenuated, remained significant. Because antidepressants may be used for conditions
beyond depression (43), we reanalyzed the data after excluding users of antidepressant medication (irrespective of
depression symptoms) from follow-up; patterns and trends
remained unchanged (Figure 1), even after adjustment.
Relative risks were 2.8 (P ¼ 0.05) for difficulty falling asleep,
4.8 (P < 0.001) for waking after sleep onset 79 minutes, and
2.9 (P ¼ 0.02) for sleep latency 14 minutes.
When standard polysomnographic cutpoints considered
clinically significant were analyzed, sleep efficiency <80%
and sleep latency >30 minutes remained significantly associated with depression (Zung score 50); total sleep time <360
minutes and waking after sleep onset 30 minutes did not.
The graded relation of total sleep time quartiles with depression was perhaps diluted by the binary cutpoint; waking after
sleep onset was significant only at upper quartile values.

Several polysomnographic cutpoints used were more conservative than those typically utilized to define poor sleep
(total sleep time <360–390 minutes, sleep efficiency <85%)
(44). Our lowest quartiles of total sleep time (<334 minutes)
and sleep efficiency (<78%) were similar to objective insomniacs’ mean values in clinical settings (329 minutes and
75%, respectively) (45), suggesting that clinically relevant
‘‘objective’’ markers were assessed. Analyses further suggested that polysomnographic markers corresponded
to self-reported difficulty in initiating and maintaining
sleep.
Among our study’s limitations, we were unable to examine whether depression was season-related (seasonal affective disorder) or to differentiate between first-onset and
recurrent depression, since information on past depression
was not available. Nevertheless, findings that insomnia
predicts depression symptoms in persons without depression
at baseline may be relevant for preventive purposes, irrespective of whether depression at follow-up is first-onset or
Am J Epidemiol 2010;171:709–720
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Table 5. Mean Scaled Zung Depression Score at 4-Year Follow-up According to Insomnia Symptoms and
Polysomnographic Markers Measured at Baselinea (n ¼ 555), Wisconsin Sleep Cohort Study, 1998–2006

Symptom or Marker

Adjustedb Mean Zung
Depression Scale
Score (Continuous
Variable)

No. of insomnia symptoms

Overall F
Test P Value

t Test P
Value

<0.0001

P for
Trend

<0.0001

0

36.57 (0.38)c

1

37.15 (0.53)

0.3674

2

40.28 (0.86)

<0.0001

3 or 4

40.03 (1.11)

0.0031

Referent

Individual insomnia symptoms
Difﬁculty falling asleep

<0.0001d

<0.0001

All symptoms ‘‘never/rarely’’

35.14 (0.66)

Difﬁculty falling asleep ‘‘sometimes’’

38.20 (0.49)

0.0002

Difﬁculty falling asleep ‘‘often/always’’

39.63 (0.89)

<0.0001

Any other symptom ‘‘sometimes/more often’’

37.03 (0.45)

0.0175

Difﬁculty getting back/returning to sleep at baseline

Referent

0.0015d

0.0005

All symptoms ‘‘never/rarely’’

35.12 (0.66)

Referent

Difﬁculty returning to sleep ‘‘sometimes’’

38.34 (0.46)

<0.0001

Difﬁculty returning to sleep ‘‘often/always’’

38.15 (0.68)

0.0014

Any other symptom ‘‘sometimes/more often’’

36.93 (0.53)

0.0300

Repeated nocturnal awakenings

<0.0001d

0.0004

All symptoms ‘‘never/rarely’’

35.12 (0.66)

Nocturnal awakenings ‘‘sometimes’’

36.87 (0.56)

0.0425

Nocturnal awakening ‘‘often/always’’

38.51 (0.48)

<0.0001

Any other symptom ‘‘sometimes/more often’’

37.82 (0.58)

Early morning awakening

Referent

0.0022
0.0088d

0.0037

All symptoms ‘‘never/rarely’’

35.13 (0.66)

Early morning awakening ‘‘sometimes’’

37.85 (0.53)

Referent
0.0014

Early morning awakening ‘‘often/always’’

37.66 (0.66)

0.0069

Any other symptom ‘‘sometimes/more often’’

37.87 (0.47)

0.0008

Polysomnographic insomnia markers
Sleep latency, minutes
14 (75th percentile)

37.88 (0.59)

<14 (referent)

37.17 (0.41)

Waking after sleep onset, minutes
79 (75th percentile)

38.68 (0.51)

<79 (referent)

36.71 (0.35)

Sleep efﬁciency, %
<78 (<25th percentile)

38.93 (0.53)

78 (referent)

36.68 (0.34)

Total sleep time, minutes

0.3207

0.3207

—e

0.0015

0.0015

—e

0.0004

0.0004

—e

0.7578

<334 (<25th percentile)

37.67 (0.64)

334–<374.5

37.38 (0.57)

374.5–<409

37.57 (0.58)

409 (referent)

36.88 (0.53)

—f

0.38

a
Participants who reported depressive symptoms (deﬁned as modiﬁed Zung depression score 50) or use of
antidepressant medication at baseline were excluded.
b
Adjusted for age, sex, and chronic health conditions.
c
Numbers in parentheses, standard error.
d
The P value for trend compares 3 categories: all symptoms ‘‘never/rarely,’’ symptom-of-interest ‘‘sometimes,’’
and symptom-of-interest ‘‘often/always’’ (any other symptom occurring ‘‘sometimes/more often’’ was excluded from
trend tests).
e
The P value for trend was redundant with the overall F test P value.
f
Because the P value from the overall F test was not signiﬁcant, pairwise t tests were not conducted.
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recurrent. Furthermore, an interaction between insomnia
and age was not observed, increasing the likelihood that
a reasonably high proportion of newly developed (vs. recurrent) depression was identified at follow-up. Self-reported depression symptoms may also be more labile.
Depression is dynamic and is characterized by symptomatic
fluidity (16, 17), suggesting that our inability to differentiate
between first-onset depression and recurrent depression may
be less pertinent.
Both early and middle insomnia—difficulty in initiating
and maintaining sleep, respectively—predicted depression
symptoms. Similarly, Perlis et al. (13) found that chronic
middle insomnia predicted depression. In contrast to our
study, they found persistent delayed (early morning
awakening) insomnia symptoms to be somewhat related
to depression and persistent early insomnia to be unrelated (13). A clinical study by Fava et al. (46) suggested
that delayed and initial insomnia are prodromal depression symptoms. Our findings that early and middle
insomnia were most related to depression are thus partially consistent with prior studies; differences may relate
to these studies’ examining chronic insomnia or clinical
populations.
The follow-up participation rate in the overall cohort has
been 80%, on average. Proportions of insomnia and depression did not vary according to number of follow-up visits
completed, suggesting an absence of selection bias. Despite
the use of polysomnography, variability (night-to-night) and
instrumentation errors were possible. However, the measurement error was probably nondifferential, thus likely
underestimating our positive findings. A first-night effect
(47) resulting in regression dilution bias is possible given
1 night of polysomnography. However, the fact that significant associations were found may highlight the strength of
our findings.
The Zung scale has limitations; it is based on self-reporting
and does not correspond directly to the criteria of the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (48). Nevertheless, its strengths include
a high correlation with clinical evaluation (38, 49) and wide
usage in research. Other potential limitations include confounding due to unmeasured factors like pain (24), though
we adjusted for back pain. The external validity of our findings should be limited to the incidence of both first-onset
and recurrent depression. Moreover, the findings may not be
generalizable beyond a middle-aged population with similar
characteristics or to persons assessed as depressed by
a clinician.
Our study’s strengths include the collection of longitudinal
data from a large population-based sample, longer follow-up,
high-quality polysomnographic and self-report assessments,
consistent findings across insomnia measures, and consideration of multiple confounding factors. Because our baseline
sample comprised mainly working persons and because we
excluded depressed participants and adjusted for common
comorbid conditions, baseline insomnia was probably unrelated to medical or psychiatric conditions. Significant results
persisted after removal of participants with anxiety, suggesting that the association observed was not merely due to
anxiety.

Conclusions

Despite its high prevalence, insomnia remains largely
undiagnosed among patients seen in primary-care settings,
due to factors ranging from inadequate training of primary
care providers to concerns and misperceptions about sleep
medications, lack of familiarity with behavioral techniques, and inadequate amounts of time spent with patients
(50). Our findings suggest that insomnia may increase the
risk of subsequent depression symptoms. If confirmed by
future studies, our results suggest that recognition and
treatment of insomnia by health-care providers may be
critical for preventing or mitigating the occurrence of depression. Prevention of depression, even mild or subthreshold depression, has wide-ranging implications given its
high (including invisible) costs (51), such as increased
health-service utilization, its chronic recurrent nature,
and undertreatment (16, 17).
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